Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

DDT: last mile in the global phase-out of its use for disease vector control?

The Lancet. Planetary health·2025

Same author

Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials.

Cancers·2025

Same author

Perceived needs of disease vector control programs: A review and synthesis of (sub)national assessments from South Asia and the Middle East.

PLoS neglected tropical diseases·2024

Same author

Assessing the implementation fidelity, feasibility, and sustainability of community-based house improvement for malaria control in southern Malawi: a mixed-methods study.

BMC public health·2024

Same author

Treatment of Progressive Cherubism during the Second Dental Transitional Phase with Calcitonin.

Case reports in dentistry·2023

Same author

Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023

Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026

Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026

Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026

Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026

Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026

Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Asparaginase revisited.

Henk van den Berg¹

¹Department of Pediatric Oncology, Emma Children Hospital Academic Medical Center, Amsterdam, The Netherlands. h.vandenberg@amc.uva.nl

Leukemia & Lymphoma

|February 2, 2011

Summary

This summary is machine-generated.

Asparaginase treatments for leukemia and lymphoma vary due to their bacterial origins, impacting efficacy and side effects. Newer formulations like PEG-asparaginase offer prolonged activity, addressing limitations of older products.

More Related Videos

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

Published on: April 9, 2017

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 4, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

Published on: April 9, 2017

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Area of Science:

Oncology
Pharmacology
Biochemistry

Background:

Asparaginase is a critical therapeutic agent for acute lymphoblastic leukemia and non-Hodgkin lymphomas.
Marketed asparaginase products are derived from bacterial sources (Escherichia coli, Erwinia chrysanthemi), leading to variability in activity, efficacy, and adverse effects.
Emerging asparaginase therapies include PEG-asparaginase and recombinant forms, with ongoing research into erythrocyte-incorporated formulations.

Purpose of the Study:

To review available data on various asparaginase preparations.
To discuss current developments in asparaginase therapy.
To compare pharmacokinetic profiles and address uncertainties regarding newer products.

Main Methods:

Review of existing literature and clinical data on asparaginase products.
Pharmacokinetic analysis comparing native and modified asparaginase formulations.
Evaluation of data on antibody formation and batch-specific differences.

Main Results:

Significant pharmacokinetic differences exist, notably the short half-life of Erwinia preparations versus the prolonged activity of PEG-asparaginase.
Variability in efficacy and side effect profiles is linked to the source organism and formulation.
Uncertainties remain regarding antibody formation and batch-to-batch consistency for newer asparaginase products.

Conclusions:

The origin and formulation of asparaginase significantly influence its pharmacokinetic properties, clinical efficacy, and safety profile.
PEG-asparaginase offers an extended duration of action compared to native Erwinia preparations.
Further research is needed to fully understand and mitigate risks associated with antibody formation and product variability in novel asparaginase therapies.